Penumbra, Inc. PEN
Updated: 6 Sep 2026
No signal published yet
We already track Penumbra and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Penumbra, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Penumbra free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On July 30, 2026, Penumbra reported its second-quarter 2026 financial results, generating $390.0 million in revenue, a 14.9% increase compared to the same period in the prior year. Revenue growth was driven by a 12.5% increase in global thrombectomy sales, which reached $259.0 million. The company remains subject to a pending acquisition by Boston Scientific Corporation for approximately $14.5 billion, which was approved by Penumbra shareholders in May 2026.
Catalysts
Regulatory decisions ahead of BSX acquisition (H2 2026)
What Firelda Watch includes for Penumbra, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Penumbra, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Penumbra free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more